Anti-allergic drug olopatadine suppresses murine contact hypersensitivity and downmodulates antigen-presenting ability of epidermal Langerhans cells.
Olopatadine hydrochloride is an H1-receptor-blocker but has other anti-allergic pharmacological potencies. We investigated whether olopatadine inhibits murine contact hypersensitivity, focussing on its modulatory action on epidermal Langerhans cells serving as antigen-presenting cells. While BALB/c mice were sensitized and challenged epicutaneously with hapten, they were administered intraperitoneally with olopatadine. Olopatadine at 1 or 0.2 mg/kg of weight significantly suppressed the sensitivity when injected at least once before sensitization or challenge. In olopatadine-injected mice, the ability of Langerhans cells to present hapten to primed T cells was reduced with decreased expression of MHC class II and co-stimulatory molecules. Langerhans cells exposed in vitro to 10(-5) or 10(-6) M olopatadine had less antigen-presenting activity than control, whereas neither T cell proliferation nor keratinocyte production of IL-1alpha and IP-10 was affected at these doses. These findings suggest that olopatadine downmodulates contact hypersensitivity at least partly by interfering with the antigen-presenting ability of Langerhans cells.
Tokura
Yoshiki
Y
Department of Dermatology, University of Occupational and Environmental Health, Kitakyushu, Japan. tokura@med.uoeh-u.ac.jp
Kobayashi
Miwa
M
Ito
Taisuke
T
Takahashi
Hideyuki
H
Matsubara
Aiko
A
Takigawa
Masahiro
M
D000818:Animals; D018926:Anti-Allergic Agents / Q000494:pharmacology; D017951:Antigen Presentation / Q000187:drug effects* / Q000276:immunology; D000954:Antigens, Surface / Q000276:immunology; D002478:Cells, Cultured; D054357:Chemokine CXCL10 / Q000276:immunology; D003877:Dermatitis, Contact / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D003990:Dibenzoxepins / Q000494:pharmacology*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation / Q000187:drug effects / Q000276:immunology; D004817:Epidermis / Q000187:drug effects* / Q000276:immunology / Q000503:physiopathology; D005260:Female; D006241:Haptens / Q000276:immunology / Q000494:pharmacology; D000949:Histocompatibility Antigens Class II / Q000187:drug effects / Q000276:immunology; D007375:Interleukin-1 / Q000276:immunology; D015603:Keratinocytes / Q000187:drug effects / Q000276:immunology; D007801:Langerhans Cells / Q000187:drug effects* / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D000069605:Olopatadine Hydrochloride; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology
D018926:Anti-Allergic Agents; D000954:Antigens, Surface; D054357:Chemokine CXCL10; D003990:Dibenzoxepins; D006241:Haptens; D000949:Histocompatibility Antigens Class II; D007375:Interleukin-1; D000069605:Olopatadine Hydrochloride